Off-label direct oral anticoagulants dosing in atrial fibrillation and venous thromboembolism is associated with higher mortality
Background Direct oral anticoagulants (DOAC) off-label use data is lacking. Our study aimed
to assess the clinical outcomes in a racially mixed population treated for atrial fibrillation (AF) …
to assess the clinical outcomes in a racially mixed population treated for atrial fibrillation (AF) …
[HTML][HTML] Direct oral anticoagulants and warfarin for venous thromboembolism treatment: trends from 2012 to 2017
Abstract Background Direct oral anticoagulants (DOACs), namely rivaroxaban, apixaban,
dabigatran, and edoxaban, are now included together with warfarin as standards of care for …
dabigatran, and edoxaban, are now included together with warfarin as standards of care for …
Edoxaban versus warfarin in patients with atrial fibrillation at the extremes of body weight: an analysis from the ENGAGE AF-TIMI 48 trial
G Boriani, CT Ruff, JF Kuder, M Shi… - Thrombosis and …, 2021 - thieme-connect.com
Background The effects of anticoagulants at extremes of body weight (BW) are not well
described. The aim of this study was to analyze the pharmacokinetics/pharmacodynamics …
described. The aim of this study was to analyze the pharmacokinetics/pharmacodynamics …
Vascular Disease Patient Information Page: Direct oral anticoagulants–2020 update
SR Vazquez - Vascular Medicine, 2020 - journals.sagepub.com
DOACs begin working faster than warfarin. They also leave the body faster than warfarin.
For example, a DOAC thins the blood and gives full blood clot protection within a few hours …
For example, a DOAC thins the blood and gives full blood clot protection within a few hours …
Non-vitamin K antagonist oral anticoagulant for atrial fibrillation in obese patients
SY Wang, RP Giugliano - The American Journal of Cardiology, 2020 - Elsevier
Highlights•Obesity is an important risk factor for atrial fibrillation.•Despite “obesity paradox”
in atrial fibrillation, patient weight loss preferred.•Oral anticoagulants may be more …
in atrial fibrillation, patient weight loss preferred.•Oral anticoagulants may be more …
Apixaban and rivaroxaban in obese patients treated for venous thromboembolism: drug levels and clinical outcomes
A Ballerie, RN Van, K Lacut, H Galinat, C Rousseau… - Thrombosis research, 2021 - Elsevier
Background Direct oral anticoagulants (DOAC) use remains challenging in obese patients
treated for Venous-Thrombo-Embolism (VTE) due to the paucity of prospective and …
treated for Venous-Thrombo-Embolism (VTE) due to the paucity of prospective and …
Dosage of anticoagulants in obesity: recommendations based on a systematic review
A Abildgaard, SA Madsen… - Seminars in thrombosis …, 2020 - thieme-connect.com
Anticoagulants are frequently used as thromboprophylaxis and in patients with atrial
fibrillation (AF) or venous thromboembolism (VTE). While obesity rates are reaching …
fibrillation (AF) or venous thromboembolism (VTE). While obesity rates are reaching …
Comparison of effectiveness, safety, and the net clinical outcome between different direct oral anticoagulants in 162,707 non-valvular atrial fibrillation patients treated …
S Deitelzweig, A Keshishian, X Li, M Hamilton… - Journal of the American …, 2018 - jacc.org
Background Most observational studies on direct oral anticoagulants (DOACs) used single
data sources with limited generalizability. This ARISTOPHANES (Anticoagulants for …
data sources with limited generalizability. This ARISTOPHANES (Anticoagulants for …
Evaluation of Apixaban safety and effectiveness in morbidly obese patients with atrial fibrillation: a retrospective cohort study
Background The benefit of apixaban to reduce stroke risk in morbidly obese patients with
nonvalvular atrial fibrillation (AF) is still undetermined. The International Society of …
nonvalvular atrial fibrillation (AF) is still undetermined. The International Society of …
Approach to the new oral anticoagulants in family practice: part 2: addressing frequently asked questions
J Douketis, AD Bell, J Eikelboom, A Liew - Canadian Family Physician, 2014 - cfp.ca
Objective To address common “what if” questions that arise relating to the long-term clinical
follow-up and management of patients receiving the new oral anticoagulants (NOACs) …
follow-up and management of patients receiving the new oral anticoagulants (NOACs) …